Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a type of lymphoma called B-cell non-Hodgkin lymphoma (B-NHL) and have completed at least one round of chemotherapy treatment.
• People with B-NHL whose cancer is in complete remission and who finished chemotherapy within the last 12 months.
• People with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) who have been taking a medication called ibrutinib for at least one month.
• People with B-NHL whose cancer has been in complete remission for more than 12 months.
• People with an aggressive form of T-cell lymphoma (called peripheral T-cell lymphoma) who have completed at least one round of chemotherapy.
• People who are able to give written or electronic consent and are willing and able to follow the study procedures and attend all required visits.
• People whose blood test results at the screening stage fall within acceptable ranges — specifically, a haemoglobin level between 7.0 and 16.1 g/dL and a platelet count between 10 and 600 per µL, or results considered not clinically significant by the study doctor.
• For one group in the trial (cohort 1): People who have not yet received a flu vaccine this season and are not suspected of having had the flu this season.
• For another group (cohort 3): People who have previously received at least one dose of a COVID-19 (SARS-CoV-2) vaccine. People who have not received a prior COVID-19 vaccine may also be eligible to enrol in this group (confirm with trial site).

Who may not be able to join:

• People who are known to be living with HIV (this information is collected by verbal report).
• People who have a medical condition that the study doctor considers to be a reason they should not participate, including any ongoing health condition lasting 3 months or longer that could put them at unacceptable risk, prevent them from completing the study requirements, or affect the assessment of results.
• People who have an acute (sudden or short-term) illness within 72 hours before receiving the study vaccine, unless the illness has nearly resolved and the study doctor considers it will not affect safety assessments — and provided it was not caused by influenza.
• People who have been taking systemic steroid medications long-term, meaning for more than 3 months in total over the past 12 months.
• People with a known allergy or hypersensitivity to eggs, egg or chicken proteins, or any other ingredient in the study vaccine.
• People who have a history of a nerve condition called Guillain-Barré syndrome (GBS).
• People who have had, or are suspected to have had, influenza (flu) during the current flu season.
• People who have abnormal vital signs or physical examination findings at screening, including a temperature of 38.0°C or higher, blood pressure outside the acceptable range, heart rate outside the acceptable range, a new rash, or signs of infection.
• People who have already received a seasonal flu vaccine during the current flu vaccination season.
• People who are enrolled in hospice care or whose life expectancy is less than 6 months.

Important: Always verify eligibility with the trial site directly before applying.